Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma…
<!-- Name:DistributionId Value:8744877 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Design Therapeutics
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216…
DT-216 was Generally Well-Tolerated and Resulted in a More than Doubling of Frataxin mRNA in Patients with Friedreich Ataxia Second GeneTACTM Development Candidate, DT-168, Selected for…
Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference
CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic…
Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of…
Topline Data from Phase 1 Trial Expected in the Second Half of 2022 DT-216 Granted FDA Fast Track Designation for Patients with Friedreich Ataxia CARLSBAD, Calif., March 30, 2022 (GLOBE…
Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy…
CARLSBAD, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today…
Design Therapeutics Announces FDA Clearance of Investigational New Drug Application…
Phase 1 Trial of DT-216 in Patients with Friedreich Ataxia to Be Initiated Soon Topline Data from Phase 1 Trial Expected in the Second Half of 2022 CARLSBAD, Calif., Feb. 28, 2022…